Furthermore, we confirmed that the impact of DLX2 on the malignancy of gastric cancer can be reversed by PI3K/AKT inhibitors, indicating that DLX2 promotes the progression of gastric cancer malignancy through the PI3K/AKT pathway (Supplementary Figure S6). The gene discussed is AKT1; the disease is gastric cancer.